Search

Your search keyword '"Kort ME"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Kort ME" Remove constraint Author: "Kort ME"
40 results on '"Kort ME"'

Search Results

2. A-995662 [(R)-8-(4-methyl-5-(4-(trifluoromethyl)phenyl)oxazol-2-ylamino)-1,2,3,4-tetrahydronaphthalen-2-ol], a novel, selective TRPV1 receptor antagonist, reduces spinal release of glutamate and CGRP in a rat knee joint pain model.

3. Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex.

4. Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis In Vivo .

5. Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Na v 1.7/ Nav1.8 blockers for the treatment of pain.

6. IL-23 induces regulatory T cell plasticity with implications for inflammatory skin diseases.

7. Inhibition of Interleukin-23-Mediated Inflammation with a Novel Small Molecule Inverse Agonist of ROR γ t.

8. Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.

9. Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists.

10. Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain.

11. TRPV1 ligands with hyperthermic, hypothermic and no temperature effects in rats.

12. Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.

13. Transient receptor potential channel ankyrin-1 is not a cold sensor for autonomic thermoregulation in rodents.

14. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.

15. Capsaicin-induced inhibition of platelet aggregation is not mediated by transient receptor potential vanilloid type 1.

16. TRPV1 antagonists: clinical setbacks and prospects for future development.

17. Synthesis of oxazolo[4,5-c]quinoline TRPV1 antagonists.

18. Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.

19. Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain.

20. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.

21. A-887826 is a structurally novel, potent and voltage-dependent Na(v)1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats.

22. Synthesis and biological evaluation of 5-substituted and 4,5-disubstituted-2-arylamino oxazole TRPV1 antagonists.

23. TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats.

24. Analgesic potential of TRPV1 antagonists.

25. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.

26. Voltage-gated sodium channel blockers for the treatment of chronic pain.

27. Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.

28. Molecular determinants of species-specific activation or blockade of TRPA1 channels.

29. A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats.

30. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.

31. Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder.

32. P2X7-related modulation of pathological nociception in rats.

33. Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener.

34. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists.

35. Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent K(ATP) opener that selectively inhibits spontaneous bladder contractions.

36. Synthesis and structure-activity relationships of a novel series of tricyclic dihydropyridine-based KATP openers that potently inhibit bladder contractions in vitro.

37. Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder.

38. Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines.

39. The pursuit of differentiated ligands for the glucocorticoid receptor.

40. Enzymatic activation of DNA cleavage by dynemicin A and synthetic analogs.

Catalog

Books, media, physical & digital resources